1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 230 results for "Acute Myeloid Leukemia (AML)".

Thumbnail for All-Oral Treatment in Patients Older Than 65 Years With Newly Diagnosed Acute Myelogenous Leukemia: Progression-Free Survival and Toxicity

AML - 843

All-Oral Treatment in Patients Older Than 65 Years With Newly Diagnosed Acute Myelogenous Leukemia: Progression-Free Survival and Toxicity

Maher Salamoon

Poster Presenter: Maher Salamoon

$Thumbnail for Efficacy and Differentiation Syndrome With Menin Inhibitors in Relapsed/Refractory KMT2A-Rearranged or NPM1-Mutated Acute Leukemia: An Exploratory Proportional Meta-Analysis$

AML - 848

Efficacy and Differentiation Syndrome With Menin Inhibitors in Relapsed/Refractory KMT2A-Rearranged or NPM1-Mutated Acute Leukemia: An Exploratory Proportional Meta-Analysis

Farzeen Fatma Syed

Poster Presenter: Farzeen Fatma Syed

SOHO 2026 Annual Meeting

Topics

All-Oral Treatment in Patients Older Than 65 Years With Newly Diagnosed Acute Myelogenous Leukemia: Progression-Free Survival and Toxicity

Efficacy and Differentiation Syndrome With Menin Inhibitors in Relapsed/Refractory KMT2A-Rearranged or NPM1-Mutated Acute Leukemia: An Exploratory Proportional Meta-Analysis

Prevalence of Standard Modifiable Risk Factors and Associated Cardiovascular Events Among Patients Hospitalized With Acute Myeloid Leukemia: A Nationwide Inpatient Analysis (2016-2022)

FIRST-LINE TREATMENT OUTCOMES IN TP53-MUTATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Comparative Toxicity of Menin Inhibitor-Based Combination therapy in newly diagnosed Acute Myeloid Leukemia: Venetoclax-containing Versus Non-Venetoclax regimens

Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016-2026)

Characteristics and Clinical Outcomes of DDX41-Mutated Myeloid Neoplasms Treated with Lenalidomide: Single-Center Retrospective Study

Treatment Intensity Does Not Improve Survival in TP53-Mutated Acute Myeloid Leukemia: Real-World Outcomes From a Racially Diverse Academic Center

Effect of Nonselective ί-Blocker Use on Postallogeneic Stem Cell Transplant Outcomes in Patients with Myeloid Neoplasms: A Trinetx-Based Retrospective Cohort Study